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Economic evaluations of lymphatic filariasis
interventions: a systematic review and
research needs
Lukyn M. Gedge1, Alison A. Bettis2,3, Mark H. Bradley4, T. Déirdre Hollingsworth5,6,7 and Hugo C. Turner8,9*
Abstract: In 2000, the World Health Organization established the Global Programme to Eliminate Lymphatic
Filariasis (GPELF), with the goal of eliminating the disease as a public health problem by 2020. Since the start
of the programme, a cumulative total of 6.2 billion treatments have been delivered to affected populations -
with more than 556 million people treated in 2015 alone. In this paper, we perform a rigorous systematic
review of the economic evaluations of lymphatic filariasis interventions have been conducted. We demonstrate that
the standard interventions to control lymphatic filariasis are consistently found to be highly cost-effective. This finding
has important implications for advocacy groups and potential funders. However, there are several important
inconsistencies and research gaps that need to be addressed as we move forward towards the 2020 elimination goals.
One of the most important identified research gaps was a lack of evaluation of new interventions specifically targeting
areas co-endemic with onchocerciasis and Loa loa - which could become a major barrier to achieving elimination.
Keywords: Lymphatic filariasis, Cost-benefit, Cost-effectiveness, Economic evaluations, Economic impact, GPELF,
Programme evaluation
Background
Lymphatic filariasis (LF), is a human disease caused by
parasitic helminths (Wuchereria bancrofti, Brugia
malayi and Brugia timori). These filarial worms are
transmitted via infected mosquitoes.
There are 73 endemic countries at-risk of LF, and
before widespread control approximately 120 million
people worldwide were infected - of whom 40 million
were suffering from overt clinical disease [1, 2]. Clin-
ical disease can manifest as painful severe swelling
due to lymphedema (an accumulation of lymphatic
fluid generally in the limbs), hydrocele (fluid accumu-
lation in the scrotal sac) and episodes of acute adeno-
lymphangitis [1, 2].
In 1997, the World Health Assembly passed Reso-
lution 50.29, calling for the elimination of LF as a public
health problem [3]. Following on from this, in 2000 the
World Health Organization (WHO) established the
Global Programme to Eliminate Lymphatic Filariasis
(GPELF) with the goal of eliminating the disease as a pub-
lic health problem by 2020 [4, 5]. The programme has two
parallel goals [4, 5]:
(i) To use community-wide annual mass drug adminis-
tration (MDA) to interrupt transmission, using a
combination of albendazole and ivermectin in areas
co-endemic with onchocerciasis, and albendazole
and diethylcarbamazine (DEC) elsewhere.
(ii)To alleviate suffering by managing morbidity and
preventing disability in clinical LF patients.
These goals are supported by the WHO’s 2020
Neglected Tropical Disease (NTD) Road Map [6] and the
London Declaration on NTDs [7].
Some countries are acknowledged as having eliminated
LF as a public health problem [8]. However, it is recog-
nised that we are not currently on track to meet these
goals in many settings, and achieving elimination may
require alternative approaches [9–11].
One particular challenge facing LF elimination efforts
in Africa is areas co-endemic with onchocerciasis and
the tropical eye worm Loa loa (which causes loiasis).
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Traditionally, onchocerciasis is managed with annual or
biannual (twice yearly) ivermectin treatment. However,
due to the potential for severe and often fatal encephalo-
pathic reactions to ivermectin in patients with high L. loa
microfilaria loads, this therapeutic approach is not permis-
sible in many loiasis co-endemic areas [12]. To facilitate
LF elimination in these problematic co-endemic zones of
central Africa, the WHO has proposed an alternative
strategy that involves biannual albendazole monotherapy
together with the expanded use of bed nets [13]. It is also
important to restate that DEC can cause severe adverse
reactions in individuals with heavy Onchocerca volvulus
infections and that it is not used in onchocerciasis-
endemic areas [14, 15].
As we move forward towards elimination, we need to
better understand the cost-effectiveness of both the
current and the potential alternative control strategies.
The aim of this paper is to provide a systematic review
of economic evaluations which have already been con-
ducted for LF interventions and to summarise the key
knowledge and research gaps in this area.
Systematic review
Search strategy and methodology
A systematic review of the literature was conducted in
December 2016 using the PubMed (MEDLINE) and ISI
Web of Science electronic databases. Variants of the
following search terms were used to find relevant
papers: lymphatic filariasis, cost(s), cost-benefit, cost-
effectiveness, economic(s), economic evaluation. No date
or language stipulations were applied to the searches. A
more detailed summary of the search terms and the
PRISMA checklist are supplied in Additional file 1.
The titles and abstracts of all the identified papers
were examined initially for relevance and then the bibli-
ographies of papers suitable for inclusion were scanned
for studies not originally retrieved from the databases.
The full selection process is outlined in Fig. 1. This
process was performed in duplicate.
Summary of the identified studies
We identified 12 different primary sources reporting the
results of economic evaluations of LF interventions. A
summary of the studies is presented in Tables 1, 2. The
majority of the estimates were evaluating MDA, though
it was not always clear which drug combination was be-
ing investigated. Only two studies were identified that
investigated the cost-effectiveness or cost-benefit of
morbidity management strategies (Tables 1, 2).
Due to the different aims of the identified studies, a
variety of different effectiveness measures were used by
the different analyses - including the cost to elimination,
cost per disability-adjusted life year (DALY) averted, the
benefit-cost ratio, the cost per case cured. Several stud-
ies [2, 16, 17] used DALYs averted as the effectiveness
measure to quantify the health impact of MDA - there-
fore their outcomes are directly comparable to each
other. The cost-effectiveness ratios varied depending on
which costs were included and the time horizon of the
analysis (Table 1). However, they all would class MDA
for LF as either cost-effective or highly cost-effective
based on the thresholds for low-income countries estab-
lished by the World Bank (≤ US$ 251 per DALY averted
= cost-effective [18], and ≤ US$ 42 per DALY = highly
cost-effective [18] (adjusting for inflation - 2016 prices)
[19]). Stone et al. [20] also used DALYs averted as an
Fig. 1 Decision tree outlining the inclusion and exclusion of the identified studies. Some studies reported both cost-benefit and cost-effectiveness
estimates. Several ‘grey literature’ texts (including policy reports) which were not found within the databases, were also identified (using Google
Scholar and the bibliographies of other papers). A PRISMA checklist is provided in Additional file 1
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effectiveness metric, and estimated the incremental cost-
effectiveness of three different scenarios for accelerating
the rate of MDA coverage scale-up (Table 1). Within this
study, they also estimated the savings to the health
system and the gains in worker productivity (Table 2).
Chu et al. [21] and Turner et al. [22] projected that the
MDA provided under the GPELF would result in substan-
tial economic benefits. The clear majority (> 80%) of this
estimated economic benefit resulted from the prevention
of the potential productivity/income losses associated with
LF morbidity (indirect costs, Table 3). These studies were
based on the same framework, and an explanation for the
differences in the results is outlined in Turner et al. [22].
Stillwaggon et al. [23] also found notable economic bene-
fits and productivity gains resulting from a community-
based lymphedema management programme in India
(Table 2).
Other studies have also highlighted the importance of
the productivity losses associated with LF morbidity
[24, 25]. For example, it has been estimated that in
India, between 3.8–8.0% of the potential male labour
input was being lost due to LF morbidity [26, 27] - sub-
sequently valued at US$ 704 million per year (1995
prices) [28]. A similar value has been reported for
Ghana, were over 7% of potential male labour was esti-
mated to be lost due to chronic LF [29]. It is note-
worthy that non-filarial elephantiasis (podoconiosis)
has also been found to be associated with significant
productivity losses [30].
It should be highlighted that these types of economic
burden/benefit estimates are highly dependent on
assumptions regarding the effect of clinical disease on
productivity [21, 31], the number of years of productive
life lived with clinical disease, and employment rates. In
addition, when comparing these estimates, it is particu-
larly important to consider which method and wage
source has been used to value the productivity losses, as
these can be highly variable even when referring to the
same type of profession (highlighted in Additional file 1:
Table S1). Furthermore, it is important to note whether
lost wages were adjusted for future inflation or for future
real wage growth (such as in [23]) as this could result in
higher economic benefits/burden estimates. All of the
studies that we found investigating the economic bene-
fits resulting from LF interventions used the human cap-
ital approach to value the prevented productivity losses.
This takes the patient’s perspective for valuing lost prod-
uctivity and therefore counts any hour not worked by
the patient as an hour lost - not accounting for the pos-
sibility that absent workers may be replaced (Table 3)
[32]. It is worth noting that an alternative method
known as the friction cost approach takes the employer’s
perspective and therefore only counts as lost, the hours
not worked before another employee takes over the
patient’s work [32]. If this approach had been used, the
estimated economic benefits could have been signifi-
cantly lower [33]. There is continued debate regarding
which approach is most appropriate [32]. Interestingly,
the second US public health service panel on “cost-ef-
fectiveness in health and medicine” recently recom-
mended using the human capital approach [34].
Only five cost-effectiveness estimates were identified
which evaluated alternative interventions to the cur-
rently recommended strategies (outlined in Table 1).
Furthermore, no studies were found that evaluated inter-
ventions specific for loiasis co-endemic areas.
The majority of the estimates had either no sensitivity
analysis conducted or only univariate sensitivity analysis
(where the impact of changing one parameter at a time
is evaluated). The two main exceptions to this were
Stone et al. [20] and Stolk et al. [35].
The assumed costs of mass drug administration
Delivery costs
When comparing the different studies, it is important to
consider that there is variation in the assumed delivery
costs of MDA, even for estimates pertaining to the same
country. The majority of the studies were based on the
same relatively small number of costing studies (Tables
1, 2), and several of the cost-effectiveness/cost-benefit
estimates were not based on published costing studies/
data. This meant it was not always clear which costs
were being included in the analyses, at times making it
difficult to judge the generalizability of these studies.
It is also important to recognise whether or not the
studies are using financial or economic cost data (Table
3). The following were the studies that clearly stated
that they are using economic costs for the investigated
intervention in at least a subset of the analysis [17, 20,
21, 35–37]. However, even in these cases it was not al-
ways clear which economic costs were being included.
For example, the economic value of the volunteer com-
munity drug distributors’ time was not always included
within the economic costs.
Drug costs
Depending on the perspective of the analysis, the value of
the donated drugs may also be included as an economic
cost. Several of the identified studies considered the eco-
nomic value of the donated drugs within their economic
evaluation - which increases the intervention’s cost (Table 4)
and therefore decreases the estimated cost-effectiveness/
cost-benefit (Table 1). However, it is important to note that
there was variation in the assumed economic value of the
drugs, and in some cases the official figures have changed
over time. For example, in 2009 GlaxoSmithKline changed
their valuation of donated albendazole to US$ 0.045 per
tablet from $0.19 per tablet (GSK, unpublished) [38]. A
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summary of the economic value of the drugs assumed by
Turner et al. [17] is outlined in Table 5.
Turner et al. [17] found that when only considering
countries using the ivermectin and albendazole regimen,
that the GPELF would no longer be classed as cost-effective
when using the World Bank thresholds (although only mar-
ginally and it remained highly cost-effective based on the
WHO-CHOICE thresholds [39]). This is due to the higher
economic value of ivermectin (Table 5). Despite this result,
the GPELF was found to be clearly cost-effective as a whole
[17]. Stolk et al. [35] also found that including the value of
the donated drugs, decreased the potential economic bene-
fits of increasing the treatment frequency to twice a year. It
should be noted that it is difficult to estimate the true eco-
nomic value of these donated drugs [17]. Furthermore, it is
important to consider that the foundation of the GPELF is
based on the long-term and sustained commitment of drug
donations of ivermectin and albendazole for as long as
needed until the elimination of LF is achieved [40], and the
majority of the required DEC is being donated up to 2020
(Table 5). It should also be noted that drug donations are
the primary basis for many NTD MDA programmes.
Table 3 Glossary
Term Definition
Benefit-cost ratio (BCR) The ratio of the monetary benefits of an intervention relative to its costs.
Cost-effectiveness ratio A statistic used to summarise the cost-effectiveness of a health care intervention. It is defined
as the cost of an intervention, divided by its effectiveness.
Direct costs Direct costs represent the value of the goods, services, and resources consumed in providing
and accessing health care. These can be split into two types: the costs borne by the health
system (such as for personnel and hospital services), and the costs borne by the patients/the
community (such as for transportation to the health facility).
Disability-adjusted life years (DALYs) DALYs are a measure of disease burden and are calculated as the sum of the years of life lost
due to premature mortality and the years of healthy life lost due to disability. The number of
years of healthy life lost due to disability are calculated using a disability weight factor (which
is between 0 and 1) that reflects the severity of the disease. One DALY can be thought of as
one year of “healthy” life lost.
Discounting/discount rate Discounting is the process of adjusting future costs and outcomes to a “present value”. The
discount rate determines the strength of the time preference.
Economic costs Economic costs represent the full value of all the resources used for an intervention – including
the value of donated resources. These are important when considering issues related to the
sustainability and replicability of interventions. Examples of resources, which often have no
financial costs but can have important economic costs are the ‘free’ use of building space
provided by Ministries of Health, and the time devoted to mass drug administration by
volunteer community drug distributors.
Economies of scale The reduction in the average cost per unit resulting from increased production/output: in this
case, the reduction in the cost per treatment as a result of increasing the number treated.
Economies of scope The reduction in the average cost per unit resulting from producing two or more products at
once: in this case, the reduction in the cost per treatment, when delivering more than one
intervention at once (i.e. integrated control programmes)
Financial costs The actual expenditure (i.e. the amount paid) for the goods and services that are purchased.
Fixed costs Costs that are not dependent on the amount of output: in this case costs that do not change
regardless of the total number of people treated.
Friction cost approach The friction cost approach takes the employer’s perspective for valuing lost productivity, and
therefore only counts as lost, the hours not worked before another employee takes over the
patient’s work [32, 33]. It is based on the assumption that an ill individual can eventually be
replaced by a healthy worker - therefore the initial productivity levels are restored after this
‘friction period’.
Human capital approach The human capital approach takes the patient’s perspective for valuing lost productivity and
therefore counts any hour not worked by the patient as an hour lost. With this approach, all
potential production not performed by a patient because of morbidity or premature mortality
is counted as a production loss [32].
Indirect costs (productivity costs): Indirect costs represent the value of the productivity losses that result from illness, treatment,
or premature death.
Perspective The study perspective is the viewpoint from which the intervention’s costs and consequences
are evaluated. When adopting the healthcare providers perspective, the costs falling outside the
healthcare sector are ignored. In contrast, when adopting the societal perspective, all relevant
cost categories should be included - including those incurred by the patients.
Time horizon The time horizon for the analysis determines the duration over which the outcomes and costs
are calculated.
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Limitations
A potential source of bias within this review is that
the employed search strategy could not always re-
trieve economic evaluations outside of published pa-
pers (i.e. grey literature such as policy documents and
reports). This bias was minimised by searching the
bibliographies of selected studies and the use of Goo-
gle Scholar. This resulted in four publications being
added to the initial compilation.
It should be noted that there could be a degree of pub-
lication bias, with economic evaluations with negative or
unfavorable results being less likely to be published.
The cost-effectiveness of control versus
elimination
When comparing the different studies, it is important to
consider the time horizon used for the analysis and
whether the study is evaluating morbidity control or the
elimination of transmission. Michael et al. [36] found that
a MDA programme’s cost per case cured can be higher
when its aim is to eliminate transmission compared to
when its aim is only morbidity control. The analysis
highlighted that a MDA programme’s peak cost-
effectiveness can occur at a point before full disease con-
trol is achieved. This is because, as the prevalence of infec-
tion decreases, the incremental cost per additional
infection cured can increase steeply for each subsequent
MDA round (illustrated in Fig. 2). However, depending on
the time horizon and assumptions of the analysis, it is
possible that an elimination campaign will become more
cost-effective in the long-term and potentially even cost-
saving (Fig. 2). For example, Remme et al. [16] found that
with a 30-year time horizon, an elimination strategy would
be more cost-effective than a morbidity control strategy
(where transmission is brought to low levels but not inter-
rupted). This was because, though an elimination strategy
is more expensive to run, after elimination has been
achieved, MDA and its associated costs stop. In contrast,
for the control scenario, transmission is not broken so the
costs associated with MDA are incurred for the full-time
horizon (Table 1). Due to this, the control scenario ultim-
ately has a higher total cost over the 30 year time horizon
(even though it was initially cheaper). It is important to
highlight that in these studies, the potential cost savings
resulting from achieving elimination/eradication are not
infinite [20, 41], as the costs being considered are re-
stricted within the study’s time horizon and are often dis-
counted into the future.
These principles are highlighted in Fig. 2. In this hypo-
thetical example, the cumulative cost of the programme
steadily increases over time but then increases at a faster
rate during the final phase of the programme - due to
Table 4 Summary of the average treatment costs of the GPELF
(2000–2014)
Cost type Average cost per
treatment (95% CI)
Financial costs US$ 0.46 (0.21–
0.76)
Economic costs - excluding the donated drugs
value
US$ 0.56 (0.25–
0.94)
Economic costs - including the donated drugs
value
US$ 1.32 (1.00–
1.69)
Notes: The shown costs represent an overall average of the GPELF (2000–2014)
adapted from Turner et al. [17]. The delivery costs were estimated using the web-
based regression MDA costing model developed by the WHO [53]. It should be
noted that model parametrisation relating to the use of paid health workers and
not community volunteers for the drug distribution was used (resulting in a higher
unit delivery cost). Further details are provided in Turner et al. [17]. Prices were
adjusted to 2014 US$ [19]
Table 5 Drug costs and their economic value
Drug and dose Average number
of tablets needed
per treatmenta
Cost/value
of each
tablet (US$)
Shipping cost
per tablet
(US$)
Average cost/value
per treatment (US$)b
Donation status
DEC (100 mg per tablet) 2.75 [35] 0.0144c Included in the
tablet cost estimate
0.044 Eisai: 2.2 billion DEC tablets to
be donated by 2020 (achieved
WHO pre-qualification in 2013).
Albendazole (400 mg per tablet) 1 [105] 0.045d [38] 0.0019 [47] 0.052 GSK: 600 million albendazole
tablets available for LF control
annually until it is eliminated as
a public health problem
Ivermectin (3 mg per tablet) 2.8 [106] 1.5e [06] 0.005e [106] 4.635 Merck & Co. Inc.: Unlimited supply
for the treatment of onchocerciasis
and LF for as long as needed
Abbreviations: LF lymphatic filariasis, GSK GlaxoSmithKline
aFor DEC and ivermectin the number of required tablets per treatment is depended on the age or height of the recipient and therefore the overall average is not
a whole number
bIncludes a wastage factor of 10%
cEisai, Unpublished
dGSK, Unpublished
eMectizan Donation Program, Unpublished. It should be noted that these are the costs/values reported by the drugs companies that donate them. However, it is
possible to procure the drugs at lower prices (see International Drug Price Indicator Guide (http://erc.msh.org/priceguide)). The table is adapted from Turner
et al. [17]
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the costs associated with scaling-up into harder-to-reach
areas, and the cost of the surveys needed to confirm the
programme can be stopped, i.e. post-MDA surveillance.
After elimination is certified, the cumulative costs stop
increasing. In contrast, the cumulative effectiveness of
the programme also increases over time, but shows a de-
gree of diminishing returns (because as the intervention
progresses fewer cases are prevented with each subse-
quent MDA round). As a result of these relationships,
the cost-effectiveness of the programme is not constant
and is highly dependent on the time horizon of the ana-
lysis. In this example, as the time horizon is increased,
the cost-effectiveness will initially increase during the
first phase of the programme but then start to decrease
due to the diminishing returns in effectiveness (as the
level of infection/transmission is reduced) and then de-
crease further when the costs rise during the final phase
of the programme. After elimination is certified, the
cost-effectiveness will steadily increase with the time
horizon, as the costs have stopped but the benefits con-
tinue to accumulate (though they are discounted into
the future). In this context, it is important to highlight
that instantaneous cost-effectiveness ratios (i.e. compar-
ing the costs and benefits at one selected time point) are
not particularly informative, and it is the total cost and
total effect for the assumed time horizon that should be
evaluated.
It is noteworthy that alternative interventions aimed at
accelerating and sustaining elimination may only have
small “incremental health gains” but a large influence on
the programme’s overall total cost (as seen for onchocer-
ciasis [42]). In such cases, an incremental cost-
effectiveness ratio in terms of the cost per additional
DALY averted may not reflect the true value of these novel
interventions. Kastner et al. [41] also highlighted that the
number of DALYs averted may not be the best measure to
assess the possible benefits of disease eradication - as the
long-term consequences and broader benefits are not ne-
cessarily fully captured. A cost-benefit analysis may be
more useful in capturing these benefits more fully.
Areas that need further research
The results of the review indicate that the standard LF
control strategies are consistently found to be cost-
effective or cost-saving. However, there are some import-
ant inconsistencies and research gaps that need to be
addressed as we move forward towards the 2020 goals,
particularly regarding the evaluation of alternative elim-
ination strategies.
In the following section we outline several key
research needs.
Settings co-endemic with loiasis
Due to the potential for life-threatening adverse
events in intensely infected L. loa patients, alternative
strategies to address the elimination of LF where
loiasis is prevalent have been proposed [12]. In 2013,
the Strategic and Technical Advisory Group for
NTDs (STAG) recommended albendazole monother-
apy combined with coordinated vector control in
areas co-endemic with loiasis [13]. The impact of this
albendazole monotherapy strategy is currently being
evaluated in parts of central Africa [13, 43] as is a
“Test-to-Exclude” from treatment approach [44].
However, none of the identified economic evaluations
focused on strategies for these co-endemic areas, and
policy for these settings is a notable research gap for
LF elimination. This gap is not necessarily surprising,
as currently the main objective and focus for these
areas is still to find strategies that work and are safe.
Fig. 2 A theoretical diagram of the potential cost, effectiveness and cost-effectiveness of a mass drug administration programme before and after
elimination. Note that this figure is illustrative and not based on primary data. The time horizon for the cost-effectiveness analysis is the duration
over which the outcomes and costs are calculated. Both the cost and effects are being discounted into the future at a rate of 3%
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It should be highlighted that the novel strategies (such
as the “Test-to-Exclude” from treatment approach) in
these settings could be more expensive than conven-
tional MDA strategies. It will be important to consider
the value of these interventions not only in reducing the
burden in co-endemic areas, but also in their capacity to
help enable the global elimination goals to be reached
and the reduced risk that sustained transmission in these
co-endemic settings results in the re-establishment of
transmission in neighbouring areas.
It is important to consider that loiasis is a vector-
borne disease (transmitted by Chrysops spp.) and an-
other potential solution for these areas is to use vector
control to reduce its transmission - reducing the overall
burden of L. loa in these population and hence to risk of
the severe adverse events associated with high microfil-
aria loads [45].
Morbidity management strategies
A key element of the WHO’s strategy to combat LF
involves increased morbidity management and disability
prevention activities [4, 46]. However, we identified only
two studies in this area - one on lymphedema manage-
ment and one on hydrocele surgery (Tables 1, 2).
To allow for more economic evaluations of LF mor-
bidity management strategies (across a range of settings),
more data are urgently needed assessing their costs,
resource requirements, clinical effectiveness, and the in-
cidence of complications/relapse for the different poten-
tial techniques.
Methodological issues and data needs
Treatment delivery costs
The costs of MDA delivery vary in different regions
(highlighted by a multi-country costing study by
Goldman et al. [47] and the systematic review by Keat-
ing et al. [24]). Understanding this variation and quanti-
fying its impact is an important research gap for future
studies - as it potentially affects the generalisability of
cost-effectiveness/cost-benefit analysis [48]. In particular,
one of the key drivers in the variation in delivery costs is
the economies of scale associated with MDA [49–51] -
the reduction in the cost per treatment as a result of in-
creasing the scale of the programme (Fig. 3). However,
the majority of studies identified in this systematic
review assumed a constant cost per treatment and did
not take into account the potential changes over time or
scale (Tables 1, 2). The economies of scale associated
with MDA are vital to consider when projecting the fu-
ture costs of LF control, as well as when estimating the
incremental costs of adopting alternative strategies.
Furthermore, additional clarity regarding which costs
are being included in the analysis will be important
in future studies.
There are few costing studies investigating alternative
strategies (such as increasing the treatment frequency
[52]) [53]. In these cases, it is vital to consider the
generalizability of the estimated difference in cost be-
tween the alternative and standard strategies across dif-
ferent programmatic settings. This is particularly
significant if the costs of the alternative strategy have
been estimated within a randomised control trial.
It should be noted that the unit delivery costs for the
programmes will likely increase considerably as they ap-
proach the “last mile” towards elimination. This is be-
cause of the increase in the costs resulting from
expanding the programmes to target harder-to-reach
areas/groups (diseconomies of scale) and costs relating
to conducting transmission assessment surveys (TAS).
This has been seen in other interventions - particularly
elimination campaigns [54–57]. Furthermore, it is im-
portant to note that as programmes start closing down
implementation units, their costs will not decrease
linearly (Fig. 3).
Programme integration
A notable research gap is the lack of understanding of
the costs of integrated NTD control [24, 58] and how
integration may influence the cost and cost-effectiveness
of implementing different control strategies (economies
of scope) (Fig. 3). Evans et al. [51] found that integrating
MDA for LF with that for schistosomiasis, STH and on-
chocerciasis in Nigeria reduced the cost per treatment
by 41% (not including the drug and overhead costs). The
role and impact of this economies of scope should be
considered further in future analyses.
Ancillary benefits of LF control programmes
The GPELF uses broad-spectrum antiparasitic drugs,
and consequently, it has substantial auxiliary benefits on
Fig. 3 Observed economies of scale and scope associated with
preventive chemotherapy. Data adapted from Evans et al. [51].
Costs are in 2008 and 2009 US$ prices
Gedge et al. Parasites & Vectors  (2018) 11:75 Page 13 of 18
other parasitic diseases such as onchocerciasis, scabies,
and the soil-transmitted helminths (STH) (described in
more detail in [2, 22]). These auxiliary benefits are not
typically included in economic evaluations of LF control
programmes, which therefore underestimates their cost-
effectiveness and cost-benefit. Furthermore, the end of
LF-related MDA programmes is likely to have a consid-
erable effect on STH transmission and prevalence, and
this potentially increased risk of STH recrudescence
needs to be evaluated [59].
Metrics and cost-effectiveness thresholds
The wide range of effectiveness metrics used by the dif-
ferent studies hinders direct comparison of their results.
This has been noted for other NTDs as well [50].
The ideal choice of metric for evaluating control strat-
egies will often be the number of DALYs averted, as it al-
lows the cost-effectiveness estimates to be directly
compared to that of other healthcare interventions. This
makes it possible to have standardised thresholds for
policymakers, which class whether or not an interven-
tion is cost-effective - which is rarely possible when
reporting a disease specific cost per infection case
averted. However, it is important to restate that, as dis-
cussed in the “The cost-effectiveness of control versus
elimination” section, DALYs averted and incremental
cost-effectiveness ratios may not reflect the true value of
alternative interventions aimed at accelerating and sus-
taining elimination or disease eradication. In addition,
DALYs are not without limitations, and their design con-
tains inherent flaws that fail to acknowledge the implica-
tions of local context on disease burden [60], which is
particularly important for NTDs which are most
prevalent in poor populations. Furthermore, clinical LF
has an impact on the quality of life for patients as well
as their families, which is not fully captured by a
DALY weight. It is also important to consider that due
to a lack of data, features of the disease burden are ig-
nored. For example, all of the current DALY estimates
for LF assume it is not associated with any excess
mortality (which could underestimate its burden). It is
also worth noting that Ton et al. [61] found that ac-
counting for the mental illness that can be experienced
by LF patients and their caregivers significantly in-
creased the DALY burden estimates related to LF. This
has not currently been included in any the economic
evaluations of LF control, which therefore underesti-
mates its cost-effectiveness/cost-benefit. Non-filarial
elephantiasis (podoconiosis) has also been found to be
associated with depression [62].
There is debate and uncertainty surrounding the most
appropriate cost per DALY averted thresholds for defin-
ing which interventions are classed as cost-effective [63,
64]. It should be noted that the thresholds established by
the World Bank [18] are more conservative than the
thresholds set by WHO-CHOICE [39] (a cost per DALY
averted > 3 times the national gross domestic product
(GDP) per capita = not cost-effective; between 1 and 3
times the national GDP per capita = “cost-effective”; and
< 1 times the national GDP per capita = “very cost-
effective”). However, these WHO thresholds are now
widely considered to be too high [63–66] and are rarely
used for NTD interventions. A recent analysis indicated
that a cost per DALY averted threshold closer to ½ the
national per capita GDP would be more appropriate for
low-income countries [67]. Interestingly, a subsequent
study used a threshold of US$ 200 per DALY averted to
identify priority interventions for consideration in low-
income countries [68].
Reporting standards for economic evaluations
Elements of the studies were not always clear, and at
times important pieces of information were not re-
ported. Moving forward it would be beneficial if studies
were to adhere more to standardised guidelines (such as
CHEERS [69]) regarding what should be reported within
the manuscript.
Evaluation of alternative interventions
Though we found five cost-effectiveness estimates relat-
ing to alternative strategies to the standard dual drug
MDA strategy (Table 1), there are still notable research
gaps in this area. In particular, the following are some
key interventions that will require further economic
evaluation in the future.
Anti-Wolbachia therapy and other novel drug treatments
A novel approach for treating LF involves using tetracyc-
line antibiotics (such as doxycycline), to target the para-
sites Wolbachia endosymbionts which are essential for
worm fertility and survival [70, 71]. A six-week course of
doxycycline has been reported as a safe and well-
tolerated treatment for LF, with significant activity
against the adult worms [71]. Treatment also improves
mild to moderate lymphoedema independent of ongoing
infection [72]. An important benefit of this intervention
is that it can also be used to treat onchocerciasis and is
safe in loiasis co-endemic areas (as L. loa do not have
any Wolbachia). One of the primary goals of the Anti-
Wolbachia Consortium (A-WOL) is to identify drugs or
regimens that reduce the period of treatment from
weeks to days [71].
Other potential macrofilaricides should also be evalu-
ated if they become available [73–79].
Triple drug administration
Triple drug administration with ivermectin, albendazole
and DEC (IDA) has been shown to keep participants free
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of microfilariae for up to two years after treatment [80]. In
contrast, within the same study over 90% of the control
group (who received the standard dual drug therapy) tested
positive for microfilaria after only one year [80]. This shows
that IDA is a more effective treatment strategy and a po-
tential method for accelerating transmission elimination
(this is supported by mathematical modelling studies [81]).
However, this strategy is not currently applicable to most
of sub-Saharan Africa, as DEC is non-permissible for use in
onchocerciasis endemic areas, and ivermectin is not rec-
ommended where intense loiasis transmission occurs [15].
Alternative approaches to manage these programmatic ex-
ceptions have been proposed [15, 44]. For example:
(i) A Test-to-Exclude from treatment strategy is cur-
rently being evaluated in loiasis-endemic areas [44].
However, were this strategy to be widely adopted, an
increase in operational costs of the LF elimination
strategy would be expected.
(ii) Pre-treatment with ivermectin in onchocerciasis en-
demic areas followed by the IDA regimen is also be-
ing considered (a “pretreat and treat” approach) [15].
Such an approach would have substantial benefits
for LF elimination and, possibly, onchocerciasis elim-
ination, but would likely also incur an increase in
programmatic costs.
Although IDA has the potential to be a game changer
for LF elimination, more research is required to deter-
mine if there is a safe and effective way to use it in co-
endemic settings before it is approved for these areas
[15]. In particular, the restrictions regarding the use of
DEC in onchocerciasis-endemic areas would need to be
addressed through robust and extensive studies showing
that IDA can be used safely in these settings [15].
Vector control
The potential impact of vector control on LF transmis-
sion has been illustrated by several studies [82]. For ex-
ample, a study in the Gambia, which found that even
without MDA, LF transmission may have been inter-
rupted through the extensive and long-term (decades)
use of insecticide-treated nets for malaria control
[83]. A malaria eradication campaign in the Solomon
Islands was also found to result in the interruption of
LF transmission in the absence of MDA [84]. In
addition, Nsakashalo-Senkwe et al. [85] found a sig-
nificant decline in LF transmission associated with
the nationwide scale-up of insecticide-treated nets in
Zambia. These studies highlight how the expansion of
insecticide-treated nets for malaria control since 2000
[86], could have had a notable impact on LF trans-
mission in some settings [87]. A more detailed review
of the role of vector control in the GPELF is pro-
vided by Bockarie et al. [82].
Due to the long-life expectancy of the adult worms
and the delay between infection and morbidity, the use
of vector control as a standalone strategy would result in
a lag before any significant effect on the prevalence of
infection and morbidity is seen [88]. This finding is
mainly because vector control programmes only reduce
exposure to new infections and do not have a direct ef-
fect on the established infections within the host popula-
tion. Although the established adult worms will die
naturally within their hosts, this occurs slowly due to
their long-life expectancy [88]. However, in combination
with MDA, vector control could potentially be beneficial
in accelerating progress to elimination, preventing trans-
mission hotspots and reducing the risk of the re-
establishment of the transmission cycle from imported
cases [82, 87–89]. This indicates that in the context of
economic evaluations, the true potential benefits of
combining vector control with MDA are long-term - in
contrast to additional short-term reductions in morbid-
ity or infection. This means that economic evaluations
of vector control would require a long-time horizon for
the analysis and a model accounting for the possibility of
elimination to capture its full long-term benefit.
It is noteworthy that the only study we identified
evaluating the cost-effectiveness of integrating vector
control with MDA (which found that it did not appear
to be cost-effective in the investigated setting [37]) had
only a five-year time horizon (Table 1). Due to this, the
potential longer-term benefits of vector control were not
necessarily fully captured.
In the context of further economic evaluations of vec-
tor control for LF, it is essential to note that its benefit
will be highly dependent on the local species of vector.
For example, bednets will not be effective in areas where
the predominant vector species bites during the day.
This highlights the importance of not overgeneralizing
the results of studies and policy in this area. It is also
important to consider issues relating to insecticide re-
sistance and the additional benefits of vector control on
other vector-borne diseases (such as dengue and mal-
aria) [90].
Diagnostics and surveillance strategies
As well as new interventions, we need to evaluate novel
diagnostics and surveillance strategies. The importance
of this research area is highlighted by a recent study
which demonstrated resurgence of transmission six years
after stopping MDA [91]. When considering new sur-
veillance strategies, it is important to note the potential
need to integrate surveillance for other NTDs (such as
STH) [92, 93]. Only one of the studies [20] we identified
explicitly considered the cost of post-MDA surveillance.
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Conclusions
LF occurs across a wide and diverse range of epidemio-
logical settings, making it difficult to draw conclusions
regarding the value of LF interventions as a whole from
studies based in a single country or setting. Also, due to
the different aims of the identified studies and the differ-
ent approaches used, it can be difficult to directly com-
pare the results of the different studies. However, overall
this systematic review highlights that the WHO recom-
mended strategies for LF elimination are consistently
found to be cost-effective or cost-saving across a wide
range of settings and assumptions. This finding has im-
portant implications for advocacy groups and potential
funders. However, there are several important research
gaps that need to be addressed as we move forward to-
wards the 2020 milestones and beyond. These include
the evaluation of alternative interventions (such as IDA,
anti-Wolbachia therapy and vector control). Further-
more, elements of the studies were not always clear, and
at times important pieces of methodological information
were not reported. Moving forward it would be benefi-
cial if studies adhered more to standardised guidelines
for reporting cost-effectiveness analysis - allowing easier
comparison of the different studies results.
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